DNA-based platform for efficient and precisely targeted bioorthogonal catalysis in living systems.

Area of Science:

• Bioorthogonal chemistry
• Nanocatalysis
• Bioconjugation

Background:

• Copper(I)-catalyzed azide-alkyne cycloaddition (CuAAC) is a key bioorthogonal reaction.
• Existing Cu(I) catalysts face challenges like toxicity, low efficiency, and lack of specific targeting in living systems.

Purpose of the Study:

• To develop a biocompatible, highly efficient, and targeted DNA-based nanocatalyst for bioorthogonal applications.
• To improve prodrug activation in cancer cells for enhanced antitumor therapy.

Main Methods:

• Design and construction of a DNA-based platform for nanocatalysis.
• In vitro evaluation of catalytic efficiency compared to traditional catalysts.
• Theoretical calculations to understand catalytic activity enhancement.
• In vitro and in vivo testing for targeted prodrug activation and antitumor efficacy.

Main Results:

• The DNA-based nanocatalyst demonstrated significantly higher catalytic efficiency (one order of magnitude) than CuSO4/sodium ascorbate.
• Theoretical calculations confirmed the role of DNA structure in enhancing catalytic activity.
• Achieved a 40-fold enhancement in prodrug activation in cancer cells via cell-specific targeting.
• Demonstrated enhanced antitumor efficacy and reduced adverse effects in vivo.

Conclusions:

• The DNA-based nanocatalyst offers a biocompatible and highly efficient alternative for bioorthogonal reactions.
• Precise targeting enables effective prodrug activation in cancer cells, leading to improved therapeutic outcomes.
• The developed system shows promise for safe and effective in vivo tumor therapy.